Abstract
We present a final analysis, including pathology review, of a cooperative group study of drug-resistant ovarian cancer. Of 200 patients registered, 112 were eligible and evaluable, with a response rate of 26% and median survival of 7 months. Because these results are poorer than those reported in the preliminary and interim analyses of this study, we scrutinized the 88 excluded patients, most of whom failed to meet our strict pathologic criteria for a diagnosis of ovarian cancer of epithelial type, and who, as a heterogeneous group, fared better than patients who did meet the eligibility criteria. We believe this analysis provides insight into the spectrum of diseases that are frequently called ovarian cancer, but might be more properly labeled abdominal carcinomatosis.
Publication types
-
Clinical Trial
-
Comparative Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Altretamine / administration & dosage
-
Altretamine / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma / drug therapy*
-
Carcinoma / mortality
-
Carcinoma / pathology
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Clinical Trials as Topic
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Drug Resistance
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Humans
-
Middle Aged
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / mortality
-
Ovarian Neoplasms / pathology
Substances
-
Doxorubicin
-
Cisplatin
-
Altretamine
-
Fluorouracil